# China Taiping Insurance

> China Taiping Insurance is a VC fund backing Biotechnology and Medical. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hong Kong, Hong Kong
- Total investments: 15
- Last investment: Dec 2025
- Lead investor: 27%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/china-taiping-insurance-hk-company-limited/
- X (Twitter): https://twitter.com/cntaiping
- Website: http://en.cntaiping.com/
- Facebook: https://www.facebook.com/ctpihk/

China Taiping Insurance is a VC fund in Hong Kong focused on Biotechnology and Medical. China Taiping Insurance Group Ltd. (“China Taiping”) is a Chinese state-owned financial and insurance group.

## Contacts

5 contacts available for China Taiping Insurance. Shizune tracks 1 team members at China Taiping Insurance. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/china-taiping-insurance?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 27% |
| Medical | 3 | 20% |
| Health Care | 3 | 20% |
| Medical Device | 3 | 20% |
| Internet | 2 | 13% |

34 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 33% |
| Series B | 3 | 20% |
| Series C | 2 | 13% |
| Funding Round | 2 | 13% |
| Venture - Series Unknown | 2 | 13% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 13 | 87% |
| Japan | 1 | 7% |
| United States | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kenneth Ng | CEO | 0 | https://shizune.co/investors/profile/kenneth-ng-4b66 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aipuqiang | Shanghai Aipuqiang Particle Equipment is committed to providing customers with independently developed advanced proton therapy systems, based on independent innovation and with the mission of creating domestically produced high-end particle therapy technology to benefit cancer patients and contribute to the Healthy China strategy. | $142.7M | Series B | Dec 27, 2025 |  |
| Kanglin Biotech | Kanglin Biotech is a national high-tech company that create first- and best-in-class revolutionary gene therapies.Kanglin Biopharma specializes in the discovery, development, and commercialization of novel gene therapy treatments for diseases that adversely impair human health, including as thalassemia, AIDS, hemophilia, and Parkinson'sdisease. |  | Series A | Sep 15, 2025 |  |
| Shenzhen Energy Environmental Protection Co. | Shenzhen Energy Environmental Protection Co. is a waste disposal company providing research, engineering design, and operation management. | $691.7M |  | Mar 11, 2025 |  |
| METiS Pharmaceuticals | METiS Pharmaceuticals is the world's first AI-driven drug formulation company. | $100M | Series C | Jun 22, 2024 |  |
| Junjiu Electronics | Junjiu Electronics is a high tech enterprise that manufactures OEMs and automotive electronic parts, provides parts testing and consulting services, SOA architecture design and development, designs technical solutions and Controller software and hardware design, development and mass production. | $14.1M | Series A | May 30, 2023 |  |
| Immunochina | ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services. |  | Venture - Series Unknown | May 08, 2023 |  |
| Evaheart | Evaheart is a supplier of medical devices. They offer products that include a hydraulically levitated impeller, an open-vane impeller with large flow gaps, pump speed modulation, and a novel double-cuff tipless inflow cannula. | $90M | Series A | Mar 09, 2023 |  |
| Doma Biopharmaceutical | Doma Biopharmaceutical is a biotech company. | $142.1M | Series A | Jun 01, 2022 |  |
| Yingsheng Biology | Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product lineincludes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level. |  | Series C | Mar 29, 2022 |  |
| China Mobile | China Mobile provides mobile telecommunications and related services in Mainland China and Hong Kong.Its portfolio of services comprises of local calls, domestic long distance calls, international long distance calls, intra-provincial roaming, inter-provincial roaming, and international roaming, caller identity display, caller restrictions, callwaiting, call forwarding, call holding, voice mail, conference calls, and others.In addition, the company offers data services, wireless data traffic services, telecommunications network planning design and consulting services, mobile data solutions, network planning and optimizing construction testing and supervising activities, technology support, designing and selling electronic communication products, and more.It was incorporated in 1997 and is based in Central, Hong Kong. China Mobile Limited is a subsidiary of China Mobile Hong Kong (BVI) Limited. | $3.8B | Post-IPO Equity | Dec 28, 2021 |  |

10 of 15 investments shown.

## Co-investors
- [Biocytogen](https://shizune.co/investors/profile/biocytogen) — VC Fund, 2 deals together
- [China Life Insurance](https://shizune.co/investors/profile/china-life-insurance) — VC Fund, 2 deals together
- [Cowin Venture](https://shizune.co/investors/profile/cowin-venture) — VC Fund, 2 deals together
- [Baidu](https://shizune.co/investors/profile/baidu) — VC Fund, 1 deal together
- [Brunei Investment Agency](https://shizune.co/investors/profile/brunei-investment-agency) — VC Fund, 1 deal together
- [CBC Capital](https://shizune.co/investors/profile/cbc-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)

## FAQ

### What does China Taiping Insurance invest in?

China Taiping Insurance invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact China Taiping Insurance?

Public channels for China Taiping Insurance include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at China Taiping Insurance?

The team at China Taiping Insurance includes Kenneth Ng (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co